Combined [18F]-FDG PET-MRI in Diagnostics and Surveillance of Small Bowel Crohn's Disease (CD-PET)

Combined [18F]-FDG PET-MRI in Diagnostics and Surveillance of Small Bowel Crohn's Disease (CD-PET)

Patients with suspected small bowel Crohn's disease (CD) are assessed with PET-MRE using 18-fluorodeoxyglucose ([18F]-FDG) tracer. Patients are recruited from the outpatient clinic of gastroenterology in Turku University Hospital. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study. This is an observational single-center imaging study.

35 patients with high clinical suspicion of active small bowel CD will be enrolled to study. After the diagnostic [18F]-FDG-PET-MRE, patients will undergo small bowel capsule endoscopy (SBCE) if no strictures are seen in PET-MRE. [18F]-FDG-PET-MRE will be repeated in 3 months after medical therapy for CD has been started. Medical therapy will be started by clinicians blinded from PET-data but have access to MRE-data and all other diagnostic measures. Adequate medication is chosen by clinicians not participating in the study and thus enrollment does not affect the choice of medical therapy for patients participating in this study. [18F]-FDG-PET-MRE and clinical assessment of disease activity will be performed within 1 month of recruitment. Follow up-visits will be arranged in the outpatient clinic of gastroenterology in Turku University Hospital.

The aim is to investigate whether [18F]-FDG-PET-MRE can be used in diagnostics and follow-up of small bowel CD and to compare its performance to MRE.

Study Overview

• Status: Completed
• Conditions: Small Bowel Crohn's Disease

Detailed Description

Diagnostics and follow up of small bowel CD can be difficult, large parts of small bowel can't be assessed by conventional endoscopy. MRE can detect transmural lesions, but sensitivity is limited with luminal disease. SBCE can detect even small lesions, but specificity is low. More accurate tools for diagnostics are hence needed. Our aim is to is to show that [18F]-FDG-PET-MRE can be used in diagnostics and disease activity monitoring of small bowel CD

Volunteer patients with clinically suspected small bowel CD (i.e. ileitis in colonoscopy, diarrhea, anemia and elevated fecal calprotectin or suspected CD in cross sectional imaging) are recruited from the outpatient clinic of gastroenterology in Turku University Hospital. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study. All patients have previously been in ileocolonoscopy.

After screening, the patients have routine blood samples taken. A complete blood count (CBC), C-reactive protein (CRP), creatinine, alanine aminotransferase (ALAT), alkaline phosphatase (AFOS) and albumin will be analyzed from each patient's blood sample and fecal calprotectin analyzed from stool. Patients are then assessed with PET-MRE using 18-fluorodeoxyglucose ([18F]-FDG) tracer. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study.

Patients fast for six hours prior to PET-MRE study. Oral mannitol is used as enteral contrast. Venous catheters will be placed at both antecubital veins for injection of [18F]-FDG and gadolinium contrast agent for MRE-sequences. Patients will lie prone for approximately 1.5h during the PET-MRE imaging. Prior to imaging, fasting glucose is measured from venous blood. During the imaging, FDG -activity will be measured from venous blood. The uptake of FDG in small bowel will be measured from the images obtained from segments with inflammation and healthy-looking segments for comparison.

If no strictures are present in the PET-MRE, the patients will go through SBCE to confirm the diagnosis of small bowel CD. The patients are arranged a visit to clinician in the outpatient clinic of gastroentereology in Turku University Hospital. The clinicians have access to MRE-data, endoscopy and SBCE-data and laboratory data, but are blinded from PET-results to avoid bias. The clinicians choose adequate treatment for each patient individually following general guidelines (such as ECCO) of treatment of small bowel CD. The patients diagnosed with small bowel CD will undergo a repeated PET-MRE following the same protocol as the first diagnostic PET-MRE to assess response to therapy. After the follow-up PET-MRE, patients medical history including laboratory and medication data will be followed and gathered for 12 months.

Primary outcome is to show that standardized uptake values (SUV) measured in [18F]-FDG-PET-MRE are higher in patients with CD than in patients not diagnosed with CD.

Secondary outcome is to show that starting effective medical therapy to small bowel CD decreases SUV in small bowel segments with CD inflammation. Secondary aim is also to investigate whether changes in SUV can predict long term disease outcomes.

• Study Type: Observational
• Enrollment (Actual): 35

Contacts and Locations

Study Locations

• Finland
  • Turku, Finland, 20521
    • Turku PET Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients are enrolled from outpatient clinic of gastroenterology of Turku University Hospital

Description

Inclusion Criteria:

• clinically suspected small bowel CD
• or ileitis in colonoscopy
• or diarrhea or anemia and elevated fecal calprotectin
• or suspected CD in cross sectional imaging)

Exclusion Criteria:

• age under 18 or above 70
• pregnancy
• metformin-medication
• claustrophobia
• previously known small bowel CD

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Study subjects; Patients with suspected small bowel Crohn's disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Standard uptake value in diagnostics of small bowel CD	Primary outcome is to show that standard uptake values (SUV) measured in [18F]-FDG-PET-MRE are higher in patients with CD than in patients not diagnosed with CD.	Immediate

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in standardized uptake values (SUV) in follow-up	Secondary outcome is to show that starting effective medical therapy to small bowel CD decreases SUV in small bowel segments with CD inflammation. Secondary aim is also to investigate whether changes in SUV can predict long term disease outcomes.	Six months

Collaborators and Investigators

• Sponsor: Turku University Hospital
• Collaborators: Mary and Georg Ehrnroot's foundation; Finnish governmental support for health sciences

Publications and helpful links

General Publications

• Mattila J, Kallio J, Loyttyniemi E, Nuutila P, Koffert J. Combined [18F]-Fluorodeoxyglucose Positron Emission Tomography-MR Imaging: A Promising Tool for Diagnostics of Small Bowel Crohn's Disease. Dig Dis. 2025;43(1):104-114. doi: 10.1159/000542379. Epub 2024 Nov 13.

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2020
• Primary Completion (Actual): October 31, 2024
• Study Completion (Actual): October 31, 2024

Study Registration Dates

• First Submitted: January 21, 2025
• First Submitted That Met QC Criteria: January 21, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 3, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: ileitis; small bowel Crohn's disease
• Additional Relevant MeSH Terms: Intestinal Diseases; Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Inflammatory Bowel Diseases; Crohn Disease
• Other Study ID Numbers: ETMK 49/2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Study data were collected from Turku University Hospital electronic patient database. Anonymized research data sets will be preserved and made accessible through the Finnish Social Science Data Archives once the whole project is finalized. Further inquiries can be directed to the primary investigator.
• IPD Sharing Time Frame: 1.8.2020-1.8.2030
• IPD Sharing Access Criteria: Anonymized research data sets will be preserved and made accessible through the Finnish Social Science Data Archives once the whole project is finalized.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No